Implications of recent statin trials for primary care practice
| Autor: | Chris J. Cadman, Peter P. Toth |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Nutrition and Dietetics Statin business.industry medicine.drug_class Endocrinology Diabetes and Metabolism nutritional and metabolic diseases Disease medicine.disease Placebo Clinical trial Internal medicine Internal Medicine medicine Cardiology lipids (amino acids peptides and proteins) cardiovascular diseases Myocardial infarction Cardiology and Cardiovascular Medicine Intensive care medicine business National Cholesterol Education Program Stroke Dyslipidemia |
| Zdroj: | Journal of clinical lipidology. 1(3) |
| ISSN: | 1933-2874 |
| Popis: | 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are the first-line treatment for dyslipidemia and the results of large statin trials have a significant impact on guidelines for cardiovascular disease (CVD) management, such as those set by the National Cholesterol Education Program Adult Treatment Panel. The benefit of statin therapy in CVD prevention has traditionally been demonstrated in clinical trials by the superior efficacy of statins vs placebo in lowering low-density lipoprotein cholesterol (LDL-C) and preventing hard coronary heart disease (CHD) outcomes including myocardial infarction and CHD death. However, due to earlier and improved treatment of CVD, the clinical manifestations of atherosclerosis are changing and other forms of CVD are now thought to predominate (such as revascularization and stroke). These changes in how CVD manifests in the patient population may have consequences for selection of endpoints when designing future clinical trials. Recent statin trials have also demonstrated the early and improved clinical benefit of lowering LDL-C beyond traditional goals with intensive statin therapy vs more moderate lipid-lowering therapy. This review assesses the impact of early statin trials on current CVD management guidelines, summarizes results of recent landmark statin trials, and evaluates the potential implications of these studies for future clinical trials and CVD management guidelines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect